Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$148 Mln
P/E Ratio
--
P/B Ratio
1.11
Industry P/E
--
Debt to Equity
-0
ROE
-0.58 %
ROCE
77.73 %
Div. Yield
0 %
Book Value
--
EPS
-0.98
CFO
$-141.19 Mln
EBITDA
$-284.95 Mln
Net Profit
$-221.50 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Silence Therapeutics PLC (SLN)
| -53.49 | -13.51 | -37.50 | -85.87 | -41.17 | -- | -- |
|
BSE Sensex*
| 1.79 | 3.57 | 5.03 | 8.98 | 11.21 | 21.06 | 11.15 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Silence Therapeutics PLC (SLN)
| -60.09 | 13.90 | -36.17 | 8.59 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 0.62 | 200.22 | -- | 299.46 | |
| 6.78 | 177.35 | -- | -40.76 | |
| 1.39 | 162.64 | -- | -136.88 | |
| 0.57 | 20.76 | 5.77 | 33.7 |
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and... rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. Address: 72 Hammersmith Road, London, United Kingdom, W14 8TH Read more
President, CEO & Executive Director
Mr. Craig A. Tooman M.B.A.
President, CEO & Executive Director
Mr. Craig A. Tooman M.B.A.
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Silence Therapeutics PLC (SLN) stood at $ 203 Mln as on 31-Dec-24
The share price of Silence Therapeutics PLC (SLN) is $3.20 (NASDAQ) as of 21-Apr-2025 16:03 EDT. Silence Therapeutics PLC (SLN) has given a return of -41.17% in the last 3 years.
Silence Therapeutics PLC (SLN) has a market capitalisation of $ 148 Mln as on 21-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Silence Therapeutics PLC (SLN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Silence Therapeutics PLC (SLN) and enter the required number of quantities and click on buy to purchase the shares of Silence Therapeutics PLC (SLN).
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. Address: 72 Hammersmith Road, London, United Kingdom, W14 8TH
The CEO & director of Mr. Craig A. Tooman M.B.A.. is Silence Therapeutics PLC (SLN), and CFO & Sr. VP is Mr. Craig A. Tooman M.B.A..
There is no promoter pledging in Silence Therapeutics PLC (SLN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
20
|
|
|
18
|
|
|
16
|
|
|
2
|
| Silence Therapeutics PLC (SLN) | Ratios |
|---|---|
|
Return on equity(%)
|
77.47
|
|
Operating margin(%)
|
-114.62
|
|
Net Margin(%)
|
-104.74
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Silence Therapeutics PLC (SLN) was $0 Mln.
$0.06
(
